Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 14Neoplasm Metastasis 6Kidney Neoplasms 5Breast Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Glioblastoma 3Urinary Bladder Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Uveal Melanoma 1Urethral Neoplasms 1Thyroid Neoplasms 1Thymoma 1Stomach Neoplasms 1Sarcoma 1Recurrence 1Ovarian Neoplasms 1Lung Neoplasms 1Hormone Refractory Prostate Cancer 1Glioma 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Fatigue 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma 1Carcinoid Tumor 1Brain Neoplasms 1

Interventions

Docetaxel 2Sunitinib 1Prednisone 1PE regimen 1Injections 1Etoposide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Hormone Refractory Prostate Cancer × Sunitinib × Clear all
NCT00795171 2010-08-18

Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer

Medical University of Vienna

Phase 2 Unknown
60 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡